HEALIOS K.K. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147 JPY | -0.68% |
|
+1.38% | -10.91% |
| Apr. 10 | Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen | MT |
| Apr. 09 | Healios K.K. Enters into Joint Research Agreement with AND Medical Group | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 101,628 | 70,754 | 16,537 | 12,300 | 13,249 | - | - |
| Enterprise Value (EV) 1 | 101,628 | 67,584 | 16,436 | 9,986 | 12,427 | 13,857 | 15,007 |
| P/E ratio | -18.3 x | -13.7 x | -2.96 x | -2.93 x | -4.43 x | -4.81 x | -5.01 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3,764 x | 1,726 x | 184 x | 102 x | 14.6 x | 9.63 x | 5.94 x |
| EV / Revenue | 3,764 x | 1,648 x | 183 x | 82.5 x | 13.7 x | 10.1 x | 6.72 x |
| EV / EBITDA | - | - | -3.43 x | -2.78 x | -14.3 x | -11.2 x | -30 x |
| EV / FCF | -23.6 x | - | - | -3.5 x | -2.12 x | -6.82 x | -5.47 x |
| FCF Yield | -4.24% | - | - | -28.5% | -47.1% | -14.7% | -18.3% |
| Price to Book | 13 x | 8.19 x | 3.87 x | 3.19 x | 3.89 x | 7.39 x | -15.9 x |
| Nbr of stocks (in thousands) | 51,666 | 55,148 | 61,704 | 74,543 | 90,130 | - | - |
| Reference price 2 | 1,967 | 1,283 | 268.0 | 165.0 | 147.0 | 147.0 | 147.0 |
| Announcement Date | 2/12/21 | 2/14/22 | 2/14/23 | 2/14/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 27 | 41 | 90 | 121 | 910 | 1,376 | 2,232 |
| EBITDA 1 | - | - | -4,793 | -3,589 | -869.5 | -1,241 | -500 |
| EBIT 1 | -4,183 | -5,384 | -5,179 | -3,379 | -2,280 | -2,226 | -1,960 |
| Operating Margin | -15,492.59% | -13,131.71% | -5,754.44% | -2,792.56% | -250.55% | -161.78% | -87.8% |
| Earnings before Tax (EBT) 1 | -5,378 | -4,462 | -5,330 | -3,626 | -2,689 | -2,410 | -2,276 |
| Net income 1 | -5,512 | -4,910 | -5,169 | -3,823 | -2,692 | -2,413 | -2,279 |
| Net margin | -20,414.81% | -11,975.61% | -5,743.33% | -3,159.5% | -295.77% | -175.33% | -102.09% |
| EPS 2 | -107.2 | -93.36 | -90.67 | -56.22 | -33.18 | -30.56 | -29.36 |
| Free Cash Flow 1 | -4,307 | - | - | -2,850 | -5,853 | -2,032 | -2,745 |
| FCF margin | -15,951.85% | - | - | -2,355.37% | -643.19% | -147.67% | -122.97% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 2/12/21 | 2/14/22 | 2/14/23 | 2/14/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q3 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14 | 20 | 10 | 11 | 11 | 22 | 8 | 60 | 7 | 101 | 108 | 6 | - | 360 | 350 | - | 500 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1,849 | -2,443 | -1,429 | -1,429 | -1,635 | -3,064 | -1,041 | -1,074 | -888 | -667 | -1,555 | -743 | -1,081 | -320 | -300 | -310 | -310 |
| Operating Margin | -13,207.14% | -12,215% | -14,290% | -12,990.91% | -14,863.64% | -13,927.27% | -13,012.5% | -1,790% | -12,685.71% | -660.4% | -1,439.81% | -12,383.33% | - | -88.89% | -85.71% | - | -62% |
| Earnings before Tax (EBT) | -2,624 | -1,807 | -1,868 | -1,415 | - | -3,213 | -1,056 | - | -735 | - | -1,321 | -709 | - | - | - | - | - |
| Net income | -2,608 | -1,892 | -1,802 | -1,460 | - | -3,260 | -696 | - | -732 | - | -1,392 | -700 | - | - | - | - | - |
| Net margin | -18,628.57% | -9,460% | -18,020% | -13,272.73% | - | -14,818.18% | -8,700% | - | -10,457.14% | - | -1,288.89% | -11,666.67% | - | - | - | - | - |
| EPS 2 | -50.82 | -36.60 | -34.81 | -26.48 | -32.63 | -59.11 | -12.02 | -19.54 | -11.51 | -10.37 | -21.88 | -9.910 | -24.43 | -4.960 | -4.960 | -4.960 | -4.960 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/6/20 | 8/10/21 | 11/12/21 | 5/10/22 | 8/9/22 | 8/9/22 | 11/14/22 | 2/14/23 | 5/12/23 | 8/14/23 | 8/14/23 | 11/14/23 | 2/14/24 | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 608 | 1,758 |
| Net Cash position 1 | - | 3,170 | 101 | 2,314 | 822 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.4899 x | -3.516 x |
| Free Cash Flow 1 | -4,307 | - | - | -2,850 | -5,853 | -2,032 | -2,745 |
| ROE (net income / shareholders' equity) | -54.6% | -59.6% | -79.4% | -92.8% | -123% | -666% | - |
| ROA (Net income/ Total Assets) | - | -18.9% | -27.3% | -24% | - | - | - |
| Assets 1 | - | 25,938 | 18,913 | 15,914 | - | - | - |
| Book Value Per Share 2 | 152.0 | 157.0 | 69.30 | 51.70 | 37.80 | 19.90 | -9.250 |
| Cash Flow per Share 2 | -103.0 | -88.40 | -83.90 | -52.90 | -35.30 | -31.60 | -21.30 |
| Capex 1 | 362 | 245 | 250 | 28 | 404 | 454 | 504 |
| Capex / Sales | 1,340.74% | 597.56% | 277.78% | 23.14% | 44.34% | 32.95% | 22.56% |
| Announcement Date | 2/12/21 | 2/14/22 | 2/14/23 | 2/14/24 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
147
JPY
Average target price
280
JPY
Spread / Average Target
+90.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.91% | 84.17M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 4593 Stock
- Financials Healios K.K.
